PB2034: CAMMA 1: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS AND ACTIVITY OF CEVOSTAMAB-CONTAINING REGIMENS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Detalles Bibliográficos
Autores principales: Vij, R., Schade, H., Trudel, S., Chang, A. C., Huang, J., Samineni, D., Sumiyoshi, T., Tsai, J., Wong, T., Harrison, S. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Publication Only
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429377/
http://dx.doi.org/10.1097/01.HS9.0000850968.59423.24

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429377/
http://dx.doi.org/10.1097/01.HS9.0000850968.59423.24

Ejemplares similares